CONCLUSIONES

 La endoteliología ha hecho cambiar la concepción de la medicina vascular, al encontrar que el endotelio no era simplemente un conjunto células "tapizadoras cual celofán". El descubrimiento de la biología del endotelio (definitivamente, estratégicamente situado), ha permitido comprender y entender que la biología molecular confluye en y hacia un punto, el cual encierra los principios y misterios de salud y enfermedad, muerte y vida. Que el equilibrio y/o la integridad del endotelio, es sinónimo de preservación de cantidad y calidad de vida y de preservación de la especie. Que la prevención primaria debe ser el objetivo para impedir un endotelio disfuncionante, cómplice o culpable de las entidades más homicidas, que un medio ambiente, libre en lo posible de polución, permitirá que la especie humana continúe sus pasos por la tierra (independientemente de la violencia) y que los médicos podemos ofrecerle a nuestros pacientes con estos conocimientos y con una farmacología adecuada, una mayor cantidad y calidad de vida, aplicando la ciencia en su dimensión perfecta, la cual deberá ser el bienestar del hombre. El endotelio nos muestra que aun hay una luz al final del túnel.

Tomado con autorización de:

La Revista MED, Volumen 13 del 2005, paginas: 45-61
Universidad Militar Nueva Granada

REFERENCIAS

1) Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxations of the arterial smooth muscle by acetylcholine. Nature 286:373-376, 1980
2) Lüscher TF, Vanhoutte PM: The Endothelium: Modulator of cardiovascular function. Boca Raton, FL (USA), CRC Inc, 1990. 3) Drexler H.. Endothelial dysfunction: clinical implication. Prog Cardiovasc Dis 1997;4:287-324.
4) Dimmeler S, Hermann C, Zeiher AM.. Apoptosis of endothelial cells. Contribution to the pathophysiology of atherosclerosis. Eur Cytokine Netw 1998;9:697-8.
5) Davies PF.. Flow-mediated endothelial mechanotransduction. Physiol Rev 1995;75:519-60
6) AW, Reidy MA, Clowes MM.. Kinetics of cellular proliferation after arterial injury I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-33. [Medline]
7) Gryglewsky RJ, Botting RM, Vane JR: Mediators produced by the endothelial cell. Hypertension 12:530-548, 1988
8) Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
9) Bhagat K, Vallance P. Nitric oxide 9 years on. J R Soc Med 1996;89:667-673.
10) Ando J, Tsuboi H, Korenaga R, Takada Y, Toyama-Sorimachi N, Miyasaka M, et al.. Shear stress inhibits adhesion of cultured endothelial cells to lymphocytes by downregulating VCAM-1 expression. Am J Physiol 1994;267:C679-87. [Medline] 11) Dimmeler S, Haendeler J, Rippmann V, Nehls M, Zeiher AM.. Shear stress inhibits apoptosis of human endothelial cells. FEBS Letters 1996;
12) Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 20. 2000;190:244-254
13) Hobbs, AJ, Higgs A, Moncada S. Inhibition of Nitric Oxide Synthase as a potential therapeutic target. Annu Rev Pharamacol Tocicol 1999; 39:191-220. 339:71-4
14) Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 1994;343:1199-1206
15) Lüscher TF, Diederich D, Siebenmann R, et al: Difference between endothelium -dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 319:462-467, 1988
16) Vanhoutte PM, Rubanyi GM, Miller VM, et al: Modulation of vascular smooth muscle contraction by the endothelium. Ann Rev Physiol 48:307-320,1986
17) Moncada S, Gryglewski RJ, Bunting S, et al: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663-665, 1976
18)Vanhoutte P. The other endothelial derived vasoactive factors. Circulation 1993, 87 (suppl V): V9-V17.
19) Ferreira SH. History of the development of inhibitors of angiotensin I conversion. Drugs 1985;30 (suppl- 1):1-5.
20) Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial
21) Lüscher T, Seo B, Bühler F. The role of endothelin in hypertension. Affirmative part of the controversy. Hypertension 1993, 21: 252-257.cells. Nature 332:411-415, 1998
22) Vanhoutte P. Vascular endothelium and Ca2+ antagonists. J Cardiovasc Pharmachol 1988, 12 (suppl 6): S21-S28
23) Lüscher T, Boulanger C, Dohi Y, et al. Endothelium-derived contracting factors. Hypertension 1991, 19:117-121.
24) Dohi Y, Hahn A, Boulanger C, Bühler F, et al. Endothelin stimulated by angiotensin II augments vascular contractility of hypertensive resistance arteries. Hypertension 1992, 19: 131-137.
25) Erdos EG. Angiontensin I converting enzyme. Circ Res 1975;36:247-54.
26) Campbell DJ. Tissue renin-angiotensin-system: sites of angiotensin formation. J Cardiovasc Pharmacol 1987;10(suppl 7):1-8.
27) Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [published errata appear in N Engl J Med 2000;342:748 and 2000;342:1376]. N Engl J Med 2000;342:145-153.
28) Vanhoutte P. The endothelium modulator of vascular smooth-muscle tone. N Engl J Med 1988, 319: 512-513.
29) Mizuno K, Tani M, Niimura S, et al. Direct evidence for local generation and release of angiotensin II in human vascular tissue. Biochem Biophys Res Commun 1989;165:457 -63.
30) De Gasparo M, Rogg H, Brink M, et al. Angiotensin II receptor subtypes and cardiac function. Eur Heart J 1994;15(Supp lD):98 -103.
31) Moncada S, Vane J. Pharmachology and endogenous roles of prostaglandin, endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1978, 30: 293-331.
32) Moncada S, Palmer RM, Higgs EA.. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43: 109-42.
33) Li J, Zhao S, Li X, et al. Non invasive detection of endothelial dysfunction in patients with essential hypertension. Int J Cardiol 1997, 61: 165-169.
34) Vanhoutte P, Boulanger C. Endotheliumdependent responses in hypertension. Hypertens Res 1995, 18: 87-98.
35) Bondjers G, Gluckhova M, Hamsson GK, Postour YV, Reidy MA, Schwatz SM. Hypertension and atherosclerosis: cause and effect, or two effects with one unknown cause. Circulation 1991;84(suppl VI):V12-16.
36) Panza J, García C, Kilcoyne C, et al. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation 1995, 91: 1732-1738.
37) A bradykynin potentiating factor (BPF) present in the venom of Bothrop jararaca. Br J Pharmacol 1965;24:163-9
38) Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998;97:596-601.
39) Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000;102:3137-3147.
40) McGovern PG, Pankow JS, Shahar E, et al. Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. N Engl J Med 1996;334:884-890.
41)LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-1357.
42) Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
43) Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126.
44) Boyle JJ, Bennett MR, Proudfoot D, et al. Human monocyte/macrophages induce human smooth muscle cell apoptosis in culture. Arterioscler Thromb Vasc Biol 2001 (in press).
45) Rangaswamy S, Penn MS, Saidel GM, Chisolm GM.. Exogenous oxidized low-density lipoprotein injures and alters the barrier function of endothelium in rats in vivo. Circ Res 1997;80:37-44.
46) Zhao B, Ehringer WD, Dierichs R, Miller FN.. Oxidized low-density lipoprotein increases endothelial intracellular calcium and alters cytoskeletal f-actin distribution. Eur J Clin Invest 1997;27:48-54
47) Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995;91:2488-2496.
48) Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973;180:1332-1339.
49) Liao JK, Shin WS, Lee WY, Clark SL.. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995;270:319-24
50) Ross R, Wight TN, Strandness E, Thiele B. Human atherosclerosis. I. Cell constitution and characteristics of advanced lesions of the superficial femoral artery. Am J Pathol 1984;114:79-93.
51) Essler M, Retzer M, Bauer M, Heemskerk JW, Aepfelbacher M, Siess W.. 11. Martínez-González J, Llorente-Cortés V, Badimon L.. Biología celular y molecular de las lesiones ateroscleróticas. Rev Esp Cardiol 2001;54:218-31.
52) Rosenfeld ME, Pestel E. Cellularity of atherosclerotic lesions. Co Art Dis 1994; 5: 189-97.
53) H Drexler: Endothelial Dysfunction.Clinical Implications. Progress Cardiovasc Dis. 1997;39:285-387
54) P Libby The interface of atherosclerosis and thrombosis: basic mechanisms Vascular Medicine 1998 3:225
55) Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90:2126-46.
56) Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
57) Zaman AG, Helft G, Worthley SG, Badimon JJ. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 2000;149:251-266.
58) Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71
59) Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503.
60) Moreno PR Bernardi VH.Lopez-Cuellar. Machhrophages, smooth muscle cells and tissue factor in unestable angina:implications for cell mediated thrombogenicity in acute coronary syndromes. Circulation 1996;94:3090-7
61) Badimón L, Martínez-González J, Royo T.. Fisiopatología de los síndromes coronarios agudos. En: Betriu E, editor.
62) Grabowski EF, Lam FP.. Endothelial cell function, including tissue factor expression, under flow conditions. Thromb Haemost 1995;74:123-8. Síndromes coronarios agudos. Madrid: Ed. Ergon S.A. 1999; p. 3-52
63) Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-1818.
64) Dessein, P.H.; Joffe, B.I.; Singh, S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis Arthritis Research & Therapy 7(3):R634-R643, 5/1/2005
65) N Curzen. Inflammation and outcome in unstable angina.Eur.Heart J 1999;20:554
66) Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-844.
67) Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-1935.
68) Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001;103:926-933.
69) Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998;98:300-307.
70) Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998;97:633-636.
71) Danesh J, Whincup P, Walker M, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ 2000;321:208-213.
72) Wald NJ, Law MR, Morris JK, et al. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study. BMJ 2000;321:204-207.
73) Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998;279:1643-1650.
74) Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001;21:115-121.
75)Asahara T, Murohara T, Sullivan A, et al. Isolation of putative endothelial progenitor cells for angiogenesis. Science 1997;275:964-967.
76)Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71-77.
77)Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952-958.
78)Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002;109:337-346.
79)Murohara T, Ikeda H, Duan J, et al. Transplanted cord blood-derived endothelial progenitor cells augment postnatal neovascularization. J Clin Invest 2000;105:1527-1536.
80)Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5:434-438.
81)Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularizatio
82)Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85:221-228.
83) Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430-436.
84)Grant MB, May WS, Caballero S, et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med 2002;8:607-612
85) Luttun A, Carmeliet G, Carmeliet P. Vascular progenitors: from biology to treatment. Trends Cardiovasc Med 2002;12:88-96